U.S. Food and Drug Administration accepts for Priority Review Bristol-Myers Squibb's application for Opdivo (nivolumab) plus Yervoy (ipilimumab) in first-line non-small cell lung cancer
Bristol-Myers Squibb Company (NYSE: BMY) announced the U.S. Food and Drug Administration (FDA) has accepted its supplemental Biologics License Application (sBLA) for Opdivo (nivolumab) in combination with Yervoy (ipilimumab) for the first-line treatment of patients with metastatic or recurrent non-small cell lung cancer (NSCLC) with no EGFR or ALK genomic tumor aberrations. (Source: World Pharma News)
Source: World Pharma News - January 17, 2020 Category: Pharmaceuticals Tags: Featured Bristol-Myers Squibb Business and Industry Source Type: news

FDA Grants Priority Review to Frontline Nivolumab-Ipilimumab Combo for NSCLC
The FDA accepted and granted priority review to the supplemental biologics license application for nivolumab in combination with ipilimumab for the first-line treatment of patients with metastatic or recurrent non-small cell lung cancer. (Source: CancerNetwork)
Source: CancerNetwork - January 15, 2020 Category: Cancer & Oncology Authors: Kristie L. Kahl Source Type: news

Immunotherapy is safe following chemoradiotherapy for women with node-positive cervical cancer
(NRG Oncology) Results from the NRG Oncology phase I clinical trial NRG-GOG 9929 show that utilizing the immunotherapy drug ipilimumab after chemoradiotherapy (CRT) is tolerated in the curative treatment of women with lymph node-positive cervical cancer. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - November 27, 2019 Category: Cancer & Oncology Source Type: news

Domenico Mallardo, MD, on Anti-CTLA4 Agents in Melanoma
Domenico Mallardo, MD, Istituto Nazionale Tumori " Fondazione Pascale " in Naples, discusses results from his trial – designed to evaluate anti-CTLA4 agents in patients with melanoma who relapsed on treatment with ipilimumab (Yervoy), which was presented at the 34th Annual Meeting& Pre-Conference Programs of the Society for Immunotherapy of Cancer (SITC 2019). (Source: CancerNetwork)
Source: CancerNetwork - November 14, 2019 Category: Cancer & Oncology Authors: Domenico Mallardo, MD Source Type: news

FDA Grants Priority Review to Opdivo-Yervoy Combo in Advanced HCC
The FDA has accepted the supplemental biologics license application and granted breakthrough therapy designation to nivolumab plus ipilimumab for the treatment of patients with advanced hepatocellular carcinoma previously treated with sorafenib. (Source: CancerNetwork)
Source: CancerNetwork - November 11, 2019 Category: Cancer & Oncology Authors: Kristie L. Kahl Source Type: news

Bristol-Myers' immunotherapies show promise in lung cancer trial; shares rise
Bristol-Myers Squibb Co said on Tuesday an interim analysis of a late-stage trial testing a combination of its immuno-oncology drugs Opdivo and Yervoy met the main goal of extending life of previously untreated lung cancer patients. (Source: Reuters: Health)
Source: Reuters: Health - October 22, 2019 Category: Consumer Health News Tags: healthNews Source Type: news

Nivolumab Therapy Prolongs Survival in Advanced Melanoma
Overall survival at five years longer with nivolumab + ipilimumab, nivolumab alone versus ipilimumab (Source: The Doctors Lounge - Oncology)
Source: The Doctors Lounge - Oncology - September 30, 2019 Category: Cancer & Oncology Tags: Dermatology, Oncology, Pharmacy, Conference News, Source Type: news

Nivolumab Therapy Prolongs Survival in Advanced Melanoma
MONDAY, Sept. 30, 2019 -- More patients with advanced melanoma receiving nivolumab plus ipilimumab or nivolumab alone have sustained long-term survival at five years compared with those receiving ipilimumab alone, according to a study published... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - September 30, 2019 Category: Pharmaceuticals Source Type: news

Could All Patients With Advanced NSCLC Go Chemo-Free? Could All Patients With Advanced NSCLC Go Chemo-Free?
Results from CheckMate 227 suggest that combination nivolumab and ipilimumab may eliminate the need for chemotherapy in advanced NSCLC, regardless of PD-L1 status.Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - September 28, 2019 Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news

One in Two Patients With Metastatic Melanoma Alive After 5 Years One in Two Patients With Metastatic Melanoma Alive After 5 Years
With the combination of ipilimumab and nivolumab, 50% of patients are still alive after 5 years, a survival rate remarkably higher than that seen with either agent alone.Medscape Medical News (Source: Medscape Pathology Headlines)
Source: Medscape Pathology Headlines - September 28, 2019 Category: Pathology Tags: Hematology-Oncology News Source Type: news

Bristol-Myers immunotherapy combo outperforms chemo in lung cancer survival: study
About 40% of patients who received a combination of Bristol-Myers Squibb Co's immuno-oncology drugs Opdivo and Yervoy as an initial treatment for advanced non-small cell lung cancer (NSCLC) were alive after two years, according to data presented at a medical meeting on Saturday. (Source: Reuters: Health)
Source: Reuters: Health - September 28, 2019 Category: Consumer Health News Tags: healthNews Source Type: news

The Kidney Cancer Association Announces Recipients for the Advanced Discovery Awards (ADA) and Young Investigator Awards (YIA)
A total of $1.3 million awarded to advance new treatments for kidney cancerHOUSTON– September 16, 2019– The Kidney Cancer Association (KCA) is pleased to announce the recipients of the Advanced Discovery Awards (ADA) and Young Investigator Awards (YIA). In April, the KCA approved $1.3 million in new grant funding to advance early detection and new treatments for kidney cancer. “The KCA was delighted by the high caliber of proposals received for both awards and are hopeful that this research will advance the medical community’s understanding of kidney cancer,” said Dr. Christopher Wood, Ch...
Source: Kidney Cancer Association - September 16, 2019 Category: Urology & Nephrology Source Type: news

Evaluating the Safety of Immunotherapy in NSCLC Patients With Comorbidities
Combination immunotherapy with nivolumab plus ipilimumab was examined as a first-line therapy for patients with  advanced non–small-cell lung cancer. Results were presented at the International Associate for the Study of Lung Cancer 2019 World Conference on Lung Cancer. (Source: CancerNetwork)
Source: CancerNetwork - September 10, 2019 Category: Cancer & Oncology Authors: Naveed Saleh, MD, MS Source Type: news

CheckMate 204 Update: Practice-Changing for Brain Metastases? CheckMate 204 Update: Practice-Changing for Brain Metastases?
New data show that ipilimumab plus nivolumab can produce a long-term response in patients with melanoma and brain metastases, says Dr Jeffrey Weber.Medscape Oncology (Source: Medscape Radiology Headlines)
Source: Medscape Radiology Headlines - September 9, 2019 Category: Radiology Tags: Hematology-Oncology Commentary Source Type: news

Nivolumab Plus Ipilimumab Beats Sunitinib for Advanced Kidney Cancer Nivolumab Plus Ipilimumab Beats Sunitinib for Advanced Kidney Cancer
Nivolumab plus ipilimumab is more effective than sunitinib as first-line treatment for patients with advanced renal-cell carcinoma (RCC), according to an extended follow-up of the ongoing CheckMate 214 trial.Reuters Health Information (Source: Medscape Allergy Headlines)
Source: Medscape Allergy Headlines - September 3, 2019 Category: Allergy & Immunology Tags: Hematology-Oncology News Source Type: news

Creating a Patient Trial Community
When TJ Sharpe was diagnosed with Stage 4 melanoma in August 2012, his future looked bleak. He was 37 years old with two young children, the median lifespan for patients with his diagnosis was 18 months and treatment options were limited.Thanks to some knowledge of the pharmaceutical industry he soon realised his best chance of survival was to find a clinical trial. It was a daunting prospect, but his resolve was solid and, after undergoing six surgical operations and four immunotherapy treatments across two different clinical trials, he lived to tell the tale.“I was lucky,” says Sharpe, “I was aware of c...
Source: EyeForPharma - August 13, 2019 Category: Pharmaceuticals Authors: Katie Osborne Source Type: news

Creating a Patient Trial Community
When TJ Sharpe was diagnosed with Stage 4 melanoma in August 2012, his future looked bleak. He was 37 years old with two young children, the median lifespan for patients with his diagnosis was 18 months and treatment options were limited.Thanks to some knowledge of the pharmaceutical industry he soon realised his best chance of survival was to find a clinical trial. It was a daunting prospect, but his resolve was solid and, after undergoing six surgical operations and four immunotherapy treatments across two different clinical trials, he lived to tell the tale.“I was lucky,” says Sharpe, “I was aware of c...
Source: EyeForPharma - August 13, 2019 Category: Pharmaceuticals Authors: Katie Osborne Source Type: news

Creating a Patient Trial Community
When TJ Sharpe was diagnosed with Stage 4 melanoma in August 2012, his future looked bleak. He was 37 years old with two young children, the median lifespan for patients with his diagnosis was 18 months and treatment options were limited.Thanks to some knowledge of the pharmaceutical industry he soon realised his best chance of survival was to find a clinical trial. It was a daunting prospect, but his resolve was solid and, after undergoing six surgical operations and four immunotherapy treatments across two different clinical trials, he lived to tell the tale.“I was lucky,” says Sharpe, “I was aware of c...
Source: EyeForPharma - August 13, 2019 Category: Pharmaceuticals Authors: Katie Osborne Source Type: news

Bristol-Myers releases mixed Opdivo lung cancer results
Bristol-Myers Squibb Co released mixed results on Wednesday from trials testing the survival benefit of its immunotherapy Opdivo in combination with either chemotherapy or its other immuno-oncology drug, Yervoy, as an initial treatment for advanced lung cancer. (Source: Reuters: Health)
Source: Reuters: Health - July 24, 2019 Category: Consumer Health News Tags: healthNews Source Type: news

ipilimumab (Yervoy)
Title: ipilimumab (Yervoy)Category: MedicationsCreated: 6/21/2019 12:00:00 AMLast Editorial Review: 6/21/2019 12:00:00 AM (Source: MedicineNet Medications General)
Source: MedicineNet Medications General - June 21, 2019 Category: Drugs & Pharmacology Source Type: news

Dr. Hussein Tawbi on Efficacy and Safety Results From the CheckMate 204 Melanoma Trial
Cancer Network spoke with Hussein Tawbi, MD, PhD, of MD Anderson Cancer Center, about the efficacy and safety of the combination of nivolumab plus ipilimumab in patients with symptomatic melanoma brain metastases. (Source: CancerNetwork)
Source: CancerNetwork - June 19, 2019 Category: Cancer & Oncology Authors: Hussein Abdul-Hassan Tawbi, MD, PhD Source Type: news

Dr. Ahmad Tarhini on Ipilimumab vs Interferon- α2b for Resected High-Risk Melanoma
Cancer Network spoke with Ahmad Tarhini, MD, PhD, about the results of the phase III  United States Intergroup E1609 trial, presented at ASCO 2019. (Source: CancerNetwork)
Source: CancerNetwork - June 12, 2019 Category: Cancer & Oncology Authors: Ahmad A. Tarhini, MD, PhD Source Type: news

Do Brain Metastases Rule Out Immunotherapy in RCC?
An interim analysis of the CheckMate 920 phase IIIb/IV trial evaluated nivolumab plus ipilimumab in advanced renal cell carcinoma patients with brain metastases. (Source: CancerNetwork)
Source: CancerNetwork - June 11, 2019 Category: Cancer & Oncology Authors: Jim Kling Source Type: news

Study Finds Modest Reality of Immunotherapy for Cancer
This study quantifies the disturbing trend that, despite the expansion in the number of patients eligible for expensive and potentially toxic ICIs [immune checkpoint inhibitors], the ratio of those benefiting is decreasing,” wrote Dr. Daniel V.T. Catenacci, co-author of an editorial that accompanied the study in JAMA Network. “Observations in this article are sobering and remind us to keep expectations realistic.” Both Catenacci and Haslem agreed that the study should serve as a reminder to patients, physicians and policy makers to have more realistic discussions about the use of, and expectations of, the...
Source: Asbestos and Mesothelioma News - June 6, 2019 Category: Environmental Health Authors: Matt Mauney Source Type: news

KEYNOTE-029: Alternate Doses of Ipilimumab Show Similar Results in Advanced Melanoma
Researchers tested standard-dose pembrolizumab plus ipilimumab at 50-mg or 100-mg doses in patients with previously untreated advanced melanoma. (Source: CancerNetwork)
Source: CancerNetwork - June 4, 2019 Category: Cancer & Oncology Authors: Lauren M. Dembeck Source Type: news

ILLUMINATE 301 Will Study Experimental Immunotherapy for Patients With Advanced Melanoma
Investigators are now enrolling for a phase III trial testing the experimental immunotherapy tilsotolimod plus ipilimumab in patients with advanced melanoma who have progressed on anti –PD-1 therapy. (Source: CancerNetwork)
Source: CancerNetwork - June 4, 2019 Category: Cancer & Oncology Authors: Lauren M. Dembeck Source Type: news

Combination checkpoint blockade effective in pre-surgical setting for early-stage lung cancers
(University of Texas M. D. Anderson Cancer Center) Neoadjuvant, or pre-surgical, treatment with nivolumab plus ipilimumab resulted in an overall major pathologic response (MPR) rate of 33 percent of treated patients with early-stage, resectable non-small cell lung cancers, meaning these patients had less than or equal to 10 percent viable tumor remaining at surgery. With these results, the combination immunotherapy met the pre-specified trial efficacy endpoint of the phase II NEOSTAR trial conducted by researchers at The University of Texas MD Anderson Cancer Center. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - June 3, 2019 Category: International Medicine & Public Health Source Type: news

Neoadjuvant Immune Checkpoint Inhibitor Combo Promising for NSCLC
Researchers compared the percentage of  non-viable tumor and tissue resident memory tumor infiltrating lymphocytes for nivolumab plus ipilimumab vs nivolumab alone. (Source: CancerNetwork)
Source: CancerNetwork - June 2, 2019 Category: Cancer & Oncology Authors: Jim Kling Source Type: news

Nivolumab with ipilimumab: Combination has added benefit in advanced renal cell carcinoma
(Institute for Quality and Efficiency in Health Care) There are advantages in overall survival, which are not offset by any disadvantages of similar importance. Extent of the added benefit depends on the patient risk scores. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - May 17, 2019 Category: International Medicine & Public Health Source Type: news

CheckMate 204:'Practice-Changing' for Metastatic Melanoma CheckMate 204:'Practice-Changing' for Metastatic Melanoma
The ipilimumab plus nivolumab combination gives patients a reasonable chance of CNS tumor regression, thus not requiring radiation, according to Jeffrey Weber.Medscape Oncology (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - April 3, 2019 Category: Consumer Health News Tags: Hematology-Oncology Commentary Source Type: news

DART: Success Story in High-Grade Neuroendocrine Carcinomas DART: Success Story in High-Grade Neuroendocrine Carcinomas
Patients with high-grade neuroendocrine carcinomas benefit from dual checkpoint inhibition with ipilimumab and nivolumab after single-agent checkpoint inhibition has failed. Is dual checkpoint blockade ready for prime time?Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - April 2, 2019 Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news

Immune checkpoint inhibitor combo efficacious for patients with neuroendocrine carcinoma
(American Association for Cancer Research) A combination of the anti-CTLA-4 immunotherapeutic ipilimumab (Yervoy) and the anti-PD-1 immunotherapeutic nivolumab (Opdivo) showed clinical benefit among patients with rare, high-grade neuroendocrine carcinoma, according to results from the DART phase II clinical trial presented at the AACR Annual Meeting 2019, March 29-April 3. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - March 31, 2019 Category: Cancer & Oncology Source Type: news

A New Dosing Regimen for Nivolumab Plus Ipilimumab in Advanced Melanoma
The  CheckMate 511 phase IIIb/IV trial investigated raising the nivolumab dose to 3 mg/kg and lowering the ipilimumab dose to 1 mg/kg. (Source: CancerNetwork)
Source: CancerNetwork - March 7, 2019 Category: Cancer & Oncology Authors: Christina Bennett, MS Source Type: news

Immunotherapy Combo Active in Metastatic Prostate Cancer Immunotherapy Combo Active in Metastatic Prostate Cancer
The combination of ipilimumab with nivolumab shows activity in advanced disease.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - February 20, 2019 Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news

Concerns Raised About Patient-Reported Outcomes in CheckMate 214 Trial
An exploratory analysis showed that patients who received  nivolumab plus ipilimumab had better patient-reported outcomes. Do the results hold up? (Source: CancerNetwork)
Source: CancerNetwork - February 13, 2019 Category: Cancer & Oncology Authors: Christina Bennett, MS Source Type: news

Mesothelioma Immunotherapy Combination Gaining Momentum
Recent studies from France and the Netherlands have shown patients with pleural mesothelioma can benefit significantly from a second-line immunotherapy drug combination. In separate phase II studies, the combination of Opdivo (nivolumab) and Yervoy (ipilimumab) created a synergy that helped stop or slow tumor growth after traditional chemotherapy had failed. “Our results add to the growing evidence that immunotherapy is a promising treatment,” wrote lead author Dr. Maria Disselhorst of the Netherlands Cancer Institute in Amsterdam. “The combination of nivolumab plus ipilimumab showed marked efficacy in pa...
Source: Asbestos and Mesothelioma News - February 11, 2019 Category: Environmental Health Authors: Daniel King Source Type: news

BMS withdraws Opdivo+Yervoy application
Bristol-Myers Squibb has withdrawn its application for FDA approval of a treatment that combined Opdivo with the drugmaker's other immune-oncology drug, Yervoy. (Source: PharmaManufacturing.com)
Source: PharmaManufacturing.com - January 24, 2019 Category: Pharmaceuticals Source Type: news

Patient-reported outcomes of patients with advanced renal cell carcinoma treated with nivolumab plus ipilimumab versus sunitinib (CheckMate 214): a randomised, phase 3 trial
In the ongoing phase 3, CheckMate 214 trial, nivolumab plus ipilimumab improved overall survival compared with sunitinib in patients with intermediate or poor risk, previously untreated, advanced renal cell carcinoma.01/23/2019 (Source: Kidney Cancer Association)
Source: Kidney Cancer Association - January 23, 2019 Category: Urology & Nephrology Source Type: news

European Commission Approves Opdivo (nivolumab) Plus Low-Dose Yervoy (ipilimumab) for First-Line Treatment of Patients with Intermediate- and Poor-Risk Advanced Renal Cell Carcinoma
Yesterday, Bristol-Myers Squibb announced that the European Commission has approved the combination of Opdivo (nivolumab) 3 mg/kg plus Yervoy (ipilimumab) 1 mg/kg ( “low-dose”) for the first-line treatment of patients with intermediate- and poor-risk advanced renal cell carcinoma (RCC).01/15/2019 (Source: Kidney Cancer Association)
Source: Kidney Cancer Association - January 15, 2019 Category: Urology & Nephrology Source Type: news

European Commission approves Opdivo (nivolumab) plus low-dose Yervoy (ipilimumab) for first-line treatment of patients with intermediate- and poor-risk advanced renal cell carcinoma
Bristol-Myers Squibb Company (NYSE: BMY) announced that the European Commission has approved the combination of Opdivo (nivolumab) 3 mg/kg plus Yervoy (ipilimumab) 1 mg/kg ("low-dose") for the first-line treatment of patients with intermediate- and poor-risk advanced renal cell carcinoma (RCC). (Source: World Pharma News)
Source: World Pharma News - January 15, 2019 Category: Pharmaceuticals Tags: Featured Bristol-Myers Squibb Business and Industry Source Type: news

Talimogene laherparepvec plus ipilimumab not cost effective
(Source: PharmacoEconomics and Outcomes News)
Source: PharmacoEconomics and Outcomes News - December 1, 2018 Category: Drugs & Pharmacology Source Type: news

EU Changes Mind on Nivo Plus Ipi for Kidney Cancer EU Changes Mind on Nivo Plus Ipi for Kidney Cancer
Positive opinions were given for the first-line use of the immunotherapy combination nivolumab and ipilimumab in kidney cancer and for an extension of indication for blinatumomab in certain leukemia patients.International Approvals (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - November 16, 2018 Category: Consumer Health News Tags: Hematology-Oncology News Alert Source Type: news

What Immunotherapy Combination Is Best in Metastatic Bladder Cancer?
Extended follow-up from the CheckMate 032 trial showed strong results with three different immunotherapy regimens involving nivolumab and ipilimumab in patients with previously treated metastatic urothelial carcinoma. (Source: CancerNetwork)
Source: CancerNetwork - November 15, 2018 Category: Cancer & Oncology Authors: Dave Levitan Source Type: news

Comparative safety of immune checkpoint inhibitors in cancer: systematic review and network meta-analysis
This review of 36 head-to-head trials found for all adverse events, the ranking was as follows for general safety (high to low): atezolizumab, nivolumab, pembrolizumab, ipilimumab and tremelimumab. Nivolumab had the best safety profile in lung cancer. (Source: Current Awareness Service for Health (CASH))
Source: Current Awareness Service for Health (CASH) - November 14, 2018 Category: Consumer Health News Source Type: news

MDACC 2018: Debate: What is the Best Front-Line Systemic Therapy for Metastatic Clear Cell Renal Cell Carcinoma?
In this article, Dr. Gao defends Nivolumab plus ipilimumab as the best front-line systemic therapy for mRCC.11/12/2018 (Source: Kidney Cancer Association)
Source: Kidney Cancer Association - November 12, 2018 Category: Urology & Nephrology Source Type: news

Radiation Could Make Mesothelioma Immunotherapy More Effective
Doctors at the Princess Margaret Cancer Center in Toronto are studying the use of hypofractionated radiation to increase the effectiveness of immunotherapy for patients with mesothelioma. They are expected to launch soon a clinical trial that will add an immunotherapy combination to the high-dose radiation and aggressive surgery mix that has been so successful in Toronto. “There are a lot of questions that still need to be answered, but if I was a betting man, I’d lay odds on it [working well],” Dr. John Cho of the cancer center’s clinical research unit, told The Mesothelioma Center at Asbestos.com....
Source: Asbestos and Mesothelioma News - November 2, 2018 Category: Environmental Health Authors: Matt Mauney Source Type: news

Nivolumab Plus Ipilimumab in Intermediate- or Poor-Risk Advanced Renal Cell Carcinoma
According to a study, patients with intermediate- or poor-risk disease, median overall survival was not estimable in the nivolumab/ipilimumab group vs 25.9 months in the sunitinib arm (hazard ratio [HR] = 0.63, P (Source: Kidney Cancer Association)
Source: Kidney Cancer Association - October 29, 2018 Category: Urology & Nephrology Source Type: news

FDA delays approval for BMS cancer therapy
Bristol-Myers said the marketing application submitted to the U.S. FDA for its Opdivo plus Yervoy cancer therapy combination will be delayed by three months, until May 2019. (Source: PharmaManufacturing.com)
Source: PharmaManufacturing.com - October 22, 2018 Category: Pharmaceuticals Source Type: news

Immunotherapy may become new first line treatment in some metastatic colorectal cancers
Immunotherapy with nivolumab and low-dose ipilimumab could become a new first line treatment in patients with some metastatic colorectal cancers following late-breaking results from the CheckMate-142 trial reported at the ESMO 2018 Congress in Munich. (1) The drug combination shrank tumours and had beneficial effects on survival in patients with microsatellite instabiliy (MSI)-high metastatic colorectal cancer. (Source: World Pharma News)
Source: World Pharma News - October 22, 2018 Category: Pharmaceuticals Tags: Featured Research Research and Development Source Type: news

Major response to immunotherapy in early-stage mismatch repair deficient colon cancer
(European Society for Medical Oncology) Pre-operative treatment with a combination of the immune checkpoint inhibitors nivolumab and ipilimumab achieves major pathological responses in 100 percent of early-stage colon cancers with mismatch repair deficiencies, according to results reported at ESMO 2018 from the first exploratory phase II trial to investigate this approach. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - October 22, 2018 Category: International Medicine & Public Health Source Type: news